The prevalence of alcohol use disorders (AUD) is a major health issue in the US, and unfortunately available therapeutics are ineffective and/or have unwanted side-effects. A new drug, 18-Methoxycoronaridine (18-MC), is an α3β4 nicotinic acetylcholine receptor (nAChR) antagonist that shows potential for reducing alcohol intake. This study further investigated 18-MC’s actions on alcohol-related behaviors and consumption. Our results highlight the involvement of α3β4 nAChRs in alcohol consumption, while 18-MC had little effect on alcohol-related behaviors.